Summary of patient characteristics for the TMA-IHC study
| . | Total number of patients in original cohort (n = 122) . | Percent of original cohort (n = 122) . |
|---|---|---|
| Male | 79 | 65 |
| Age >45 y | 27 | 22 |
| Advanced (stage IIB-IV) | 87 | 71 |
| Anthracycline-based chemotherapy | 56 | 46 |
| Alkylator-based chemotherapy | 52 | 43 |
| Radiotherapy only | 14 | 11 |
| Combined modality | 48 | 39 |
| Histological subtype | ||
| Nodular sclerosis | 93 | 78 |
| Mixed cellularity | 25 | 20 |
| Classical lymphocyte rich | 0 | — |
| Lymphocyte deplete | 2 | 2 |
| EBER-ISH + | 38 | 31 |
| . | Total number of patients in original cohort (n = 122) . | Percent of original cohort (n = 122) . |
|---|---|---|
| Male | 79 | 65 |
| Age >45 y | 27 | 22 |
| Advanced (stage IIB-IV) | 87 | 71 |
| Anthracycline-based chemotherapy | 56 | 46 |
| Alkylator-based chemotherapy | 52 | 43 |
| Radiotherapy only | 14 | 11 |
| Combined modality | 48 | 39 |
| Histological subtype | ||
| Nodular sclerosis | 93 | 78 |
| Mixed cellularity | 25 | 20 |
| Classical lymphocyte rich | 0 | — |
| Lymphocyte deplete | 2 | 2 |
| EBER-ISH + | 38 | 31 |